Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 10/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 6/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517783 | 0.88 | KAT2B (0.44) | KAT2BBPTFCCNT1CCNKCCNE1 | |
| SCHEMBL30517804 | 0.83 | EHMT2 (0.43) | KAT2BBPTFCCNT1CCNKCCNE1 | |
| SCHEMBL30055172 | 0.77 | IL1B (0.40) | KAT2BIL1B | |
| SCHEMBL30517822 | 0.76 | EHMT2 (0.43) | KAT2BBPTFCCNT1CCNKCCNE1 | |
| SCHEMBL25300741 | 0.75 | BTK (0.50) | — | |
| SCHEMBL25262909 | 0.75 | BTK (0.50) | — | |
| SCHEMBL25294649 | 0.75 | KAT2B (0.45) | KAT2BBPTFCCNT1CCNKCCNE1 | |
| SCHEMBL25253097 | 0.75 | KAT2B (0.41) | KAT2BBPTFIL1BNLRP3 | |
| SCHEMBL25294648 | 0.75 | KAT2B (0.45) | KAT2BBPTFCCNT1CCNKCCNE1 | |
| SCHEMBL25294680 | 0.75 | KAT2B (0.41) | KAT2BBPTFIL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |